Cynthia Self, MD
Ophthalmology · Bangor, MENPI 1275521650
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,641 of the $3,156 with a category attached, or 83.7%. 16 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 34.7% of the total. Among ophthalmology clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- AbbVie$315
- Steris Corporation$275
- Aerie Pharmaceuticals, Inc.$247
- Bausch & Lomb Americas Inc.$181
- Oyster Point Pharma, Inc.$169
- plus $873 from 10 others
What the payments were for
- Food & beverage$2,64184%
- Education$47015%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 47 | $1,096 |
| AbbVie(2 entities) | 14 | $315 |
| Steris Corporation | 6 | $275 |
| Aerie Pharmaceuticals, Inc. | 17 | $247 |
| Bausch & Lomb Americas Inc. | 7 | $181 |
| Oyster Point Pharma, Inc. | 7 | $169 |
| Alcon | 7 | $169 |
| Dompe US, Inc. | 5 | $122 |
| ANI Pharmaceuticals, Inc. | 4 | $101 |
| Sun Pharmaceutical Industries Inc. | 6 | $96 |
| Amgen(2 entities) | 5 | $96 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $67 |
| Tarsus Pharmaceuticals, Inc. | 2 | $62 |
| Novartis | 3 | $56 |
| Glaukos Corporation | 2 | $56 |
| Biotissue Holdings Inc. | 3 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NA$100
How this compares
$3,156 in reported general payments places this provider in the 90th percentile of 74 ophthalmology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 40 | $53,537 |
| LumiganBimatoprost | 67 | $45,432 |
| Prednisolone Acetate | 711 | $27,880 |
| Alphagan PBrimonidine Tartrate | 40 | $20,091 |
| MieboPerfluorohexyloctane/Pf | 15 | $16,400 |
| MoxifloxacinMoxifloxacin Hcl | 618 | $13,605 |
| Fluorometholone | 95 | $10,544 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $10,014 |
| Brimonidine Tartrate | 54 | $9,088 |
| RhopressaNetarsudil Mesylate | 17 | $8,427 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 34 | $8,143 |
| Travoprost | 45 | $8,034 |
| Cyclosporine | 13 | $6,418 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $4,698 |
| Latanoprost | 282 | $4,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $315 | $123,759162 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $247 | $18,44029 claims |
| Bausch & Lomb Americas Inc.Miebo | $181 | $16,40015 claims |
| AlconSimbrinza | $169 | $8,14334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 ophthalmology providers in Maine.
Other ophthalmology in Bangor
- Curt YoungBangor$5K
- Oscar BatlleBangor$3K
- Tracey DurkovichBangor$2K
- Lawrence PiazzaBangor$2K
- Garth WilbanksBangor$1K
- Marina PeskinaBangor$610
- Jessica WatsonBangor$386
- Jeffrey JordanBangor$325
- Charles ZacksPortland$36K
- Martin WhitakerNorway$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.